Beyond Air (Beyond Air) FCF Margin % : -3,875.70% (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Beyond Air FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Beyond Air's Free Cash Flow for the three months ended in Dec. 2023 was $-15.15 Mil. Beyond Air's Revenue for the three months ended in Dec. 2023 was $0.39 Mil. Therefore, Beyond Air's FCF Margin % for the quarter that ended in Dec. 2023 was -3,875.70%.

As of today, Beyond Air's current FCF Yield % is -110.44%.

The historical rank and industry rank for Beyond Air's FCF Margin % or its related term are showing as below:

XAIR' s FCF Margin % Range Over the Past 10 Years
Min: -8645.14 Med: -1100.29 Max: 16.64
Current: -8645.14

During the past 9 years, the highest FCF Margin % of Beyond Air was 16.64%. The lowest was -8645.14%. And the median was -1100.29%.

XAIR's FCF Margin % is ranked worse than
97.94% of 824 companies
in the Medical Devices & Instruments industry
Industry Median: -7.275 vs XAIR: -8645.14

Beyond Air FCF Margin % Historical Data

The historical data trend for Beyond Air's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beyond Air FCF Margin % Chart

Beyond Air Annual Data

Trend

Jun15

Jun16

Dec17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

FCF Margin %

Get a 7-Day Free Trial

16.64

-1,100.29

-2,351.55

Beyond Air Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-	-	-30,420.34	-6,694.98	-3,875.70

Competitive Comparison of Beyond Air's FCF Margin %

For the Medical Devices subindustry, Beyond Air's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Beyond Air's FCF Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Beyond Air's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Beyond Air's FCF Margin % falls into.

Beyond Air FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Beyond Air's FCF Margin for the fiscal year that ended in Mar. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Mar. 2023 )	/	Revenue (A: Mar. 2023 )
	=	-36.886	/	0
	=	%

Beyond Air's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-15.154	/	0.391
	=	-3,875.70 %

Beyond Air FCF Margin % Related Terms

Thank you for viewing the detailed overview of Beyond Air's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Beyond Air (Beyond Air) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Beyond Air Inc (NAS:XAIR) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

48L:Germany

Address

900 Stewart Avenue, Suite 301, Garden City, New York, NY, USA, 11530

Website

https://www.beyondair.net

Beyond Air Inc is a clinical-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.

Executives

Amir Avniel	director, officer: President & CEO	2 ILAN RAMON, SCIENCE PARK, NESS ZIONA L3 7403635
Jeff Lynn Myers	officer: Chief Medical Officer	C/O BEYOND AIR, INC., 900 STEWART AVENUE, SUITE 301, GARDEN CITY NY 11530
Robert Carey	director	HORIZON PHARMA, INC., 520 LAKE COOK ROAD, SUITE 520, DEERFIELD IL 60062
Steven A. Lisi	director	2 ILAN RAMON, SCIENCE PARK, NESS ZIONA L3 7403635
Michael A. Gaul	officer: Chief Operating Officer	425 MARTINGALE ROAD, SUITE 1000, SCHAUMBURG IL 60173-2213
William P Forbes	director	C/O SALIX PHARMACEUTICALS, LTD., 8510 COLONNADE CENTER DRIVE, RALEIGH NC 27615
Yoori Lee	director	C/O AIT THERAPEUTICS, INC., 500 MAMARONECK AVENUE, HARRISON NY 10528
Ron Bentsur	director	750 LEXINGTON AVE, 20TH FL, NEW YORK NY 10022
Erick Lucera	director	138 THISTLE ROAD, NORTH ANDOVER MA 08145
Douglas Quinton Larson	officer: Chief Financial Officer	BEYOND AIR, INC., 900 STEWART AVENUE, SUITE 301, GARDEN CITY NY 11530
Douglas Beck	officer: Chief Financial Officer	C/O IBIO, INC., 9 INNOVATION WAY, SUITE 100, NEWARK DE 19711
Ari Raved	director	2 ILAN RAMON, SCIENCE PARK, NESS ZIONA L3 7403635
Jerome B Zeldis	director	8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
David Grossman	director	2 ILAN RAMON, SCIENCE PARK, NESS ZIONA L3 7403635
Haim Aviv	officer: Chief Financial Officer	2 ILAN RAMON, SCIENCE PARK, NESS ZIONA L3 7403635